Stock Buyback Program Authorized by Express Scripts (NASDAQ:ESRX) Board of Directors

Express Scripts (NASDAQ:ESRX) declared that its Board of Directors has authorized a share repurchase plan, which permits the company to repurchase 45,000,000 outstanding shares on Monday, December 18th, EventVestor reports. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Shares of Express Scripts (NASDAQ ESRX) traded down $0.26 during mid-day trading on Thursday, reaching $80.09. The company’s stock had a trading volume of 5,054,100 shares, compared to its average volume of 4,330,000. The stock has a market capitalization of $45,510.00, a P/E ratio of 13.30, a P/E/G ratio of 1.01 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.73 and a debt-to-equity ratio of 0.86. Express Scripts has a 52 week low of $55.80 and a 52 week high of $81.04.

Express Scripts (NASDAQ:ESRX) last released its earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, meeting the consensus estimate of $1.90. The business had revenue of $24.68 billion for the quarter, compared to the consensus estimate of $25.68 billion. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.74 earnings per share. equities research analysts anticipate that Express Scripts will post 7.04 EPS for the current year.

ESRX has been the topic of a number of research reports. Maxim Group increased their price objective on Express Scripts from $78.00 to $87.00 and gave the company a “buy” rating in a report on Thursday, December 14th. Raymond James Financial reissued an “underperform” rating on shares of Express Scripts in a report on Monday, October 9th. Zacks Investment Research lowered Express Scripts from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. Deutsche Bank began coverage on Express Scripts in a report on Monday, December 4th. They issued a “buy” rating and a $75.00 price objective on the stock. Finally, Royal Bank of Canada set a $66.00 target price on Express Scripts and gave the stock a “hold” rating in a research note on Wednesday, October 25th. Five equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $76.52.

In other Express Scripts news, VP Phyllis S. Anderson sold 643 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $62.37, for a total transaction of $40,103.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Glen D. Stettin sold 3,448 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $76.00, for a total value of $262,048.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,195 shares of company stock worth $1,010,240. Company insiders own 0.68% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at

Express Scripts Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with's FREE daily email newsletter.

Leave a Reply